DeCODE, which was a very fancy Icelandic company roughly in the same niche as 23andme (founded in the 1990s!), also got bought by a pharma. Amgen in their case.

DeCODE, which was a very fancy Icelandic company roughly in the same niche as 23andme (founded in the 1990s!), also got bought by a pharma. Amgen in their case. For more background, see: https://en.wikipedia.org/wiki/DeCODE_genetics https://en.wikipedia.org/wiki/DeCODE_genetics. Genetic information is valuable for finding drug targets, but it's generally a poor predictor of disease, except in case of rare monogenic disorders. With the advent of large population studies such as UK Biobank, which include lots of epigenetic information as well, I am not sure if one can get much extra value from 23andme's dataset in a pharmaceutical context.